Identifiants chercheur

Nombre de documents

20

Aurélie Mahalatchimy


Aurélie Mahalatchimy is an academic lawyer (PhD in law from the University of Toulouse, France). She is permanent Researcher at the French National Centre for Scientific Research (CNRS, chargée de recherche), Aix Marseille University, Toulon University, Pau & Pays AdourUniversity, International, Comparative and European laws (DICE- CERIC) research lab, Aix-en-Provence, France. She is also Associated researcher to the Centre for Global Health Policy, School of Global Studies, University of Sussex, UK.

Aurélie’smain research interest is International, European and Comparative law of biomedical innovations, especially the uses of human genes, cells and tissues for therapeutic (advanced therapy medicinal products), scientific, commercial and industrial purposes.

She has been involved in various International, European, French and UK research projects. She published 52 articles, including 23 in peer-reviewed journals, co-coordinated a special issue of the French review Quaderni on Human as therapeutics, and presented 50 communications, including 13 as invited speaker.


Article dans une revue9 documents

  • Aurélie Mahalatchimy. Médicaments de thérapie innovante et gestion des risques : quelle place pour le principe de précaution?. Revue du droit de l'Union européenne, Editions Clément Juglard, A paraître. 〈halshs-01938316〉
  • Aurélie Mahalatchimy. Pour une stratégie de l’Union européenne dans le domaine de l’innovation en santé. Revue de l'Union Européenne, Dalloz, A paraître. 〈halshs-01938307〉
  • Alice Yuen-Ting Wong, Aurélie Mahalatchimy. Human stem cells patents-Emerging issues and challenges in Europe, United States, China, and Japan. The Journal of World Intellectual Property, In press, 〈10.1111/jwip.12098〉. 〈halshs-01756840〉
  • Alex Faulkner, Aurélie Mahalatchimy. The politics of valuation and payment for regenerative medicine products in the UK. New Genetics and Society, Taylor & Francis (Routledge), 2018, 〈10.1080/14636778.2018.1487282〉. 〈halshs-01856030〉
  • Aurélie Mahalatchimy, Nathalie De Grove-Valdeyron. Les essais cliniques de médicaments de thérapie innovante: quel avenir pour la réglementation européenne?. Journal International de Bioéthique et d'Ethique des Sciences, ESKA, 2018, Les médicaments innovants / Innovative drugs, 29 (2), pp.35-51. 〈http://eska-publishing.com/fr/journal-international-de-bioethique/1132904-ib2018200-consulter-le-numero-2-regards-croises-sur-l-embryon-40-ans-apres-la-loi-veil.html〉. 〈10.3917/jibes.292.0035〉. 〈halshs-01856035〉
  • Aurélie Mahalatchimy. La promotion de l’innovation en matière de santé: quelles logiques à l’œuvre dans l’Union européenne?. Revue des Affaires européennes/Law European & Affairs, Bruylant / Larcier (en ligne), 2018. 〈halshs-01829689〉
  • Virginie Tournay, Annette Leibing, Aurélie Mahalatchimy, Coralie Mounet, Guy Saez. Ceci n’est pas une cellule souche. Du laboratoire au musée : le défi de la compréhension de la complexité biologique. Recherches en didactique des sciences et des technologies - RDST, 2018, Chercheurs en didactique, enseignants et formateurs : perspectives et collaborations, 〈10.4000/rdst.1724〉. 〈halshs-01938277〉
  • Aurélie Mahalatchimy, Alex Faulkner. The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics. Regenerative Medicine, Future Medicine, 2017, pp.611 - 622. 〈10.2217/rme-2017-0041〉. 〈halshs-01609518〉
  • Emmanuelle Rial-Sebbag, Aurélie Mahalatchimy, Anne-Marie Duguet. Cells’ safety in the European towards an Ethical Safety. International Journal of Bioethics, Diffusion Eska, 2017. 〈halshs-01743811〉

Chapitre d'ouvrage2 documents

  • Aurélie Mahalatchimy, Anne-Marie Duguet, Wen Meng, Heidi Howard, Anne Cambon-Thomsen, et al.. In need for a modern Daedalus? The challenging regulatory path for marketing gene therapy medicinal products in China and Europe. Q. Yanping, A.-M. Duguet. Biotechnology Medicine and Law, China University of Political Science and Law Press, 2018, 978-7-5620-8420-4. 〈halshs-01938345〉
  • Anne-Marie Duguet, Emmanuelle Rial-Sebbag, Aurélie Mahalatchimy, Mou Li, Anne Cambon-Thomsen. Ethical and legal frameworks for embryonic stem-cell based research in France and in Europe: a challenge for biotechnology. CUPL. Biotechnology Medicine and Law, 2018, 978-7-5620-8420-4. 〈halshs-01938427〉

Communication dans un congrès5 documents

  • Aurélie Mahalatchimy, Alex Faulkner, Andrew Webster. Introduction to the session on the values of biomedical innovation. EuroScience Open Forum, Jul 2018, Toulouse, France. 〈halshs-01938459〉
  • Aurélie Mahalatchimy. Medical devices vs medicinal products: what is the impact of the recent European regulatory changes?. Annual Meeting on Law & Society, Jun 2018, Toronto, Canada. 〈halshs-01938450〉
  • Aurélie Mahalatchimy. How can we facilitate the delivery of advanced therapies to patients? . 44th ANNUAL MEETING of the European Society for Blood and Marrow Transplantation (EBMT2108), Mar 2018, Lisbonne, Portugal. 〈http://ebmt2018.org/〉. 〈halshs-01769053〉
  • Aurélie Mahalatchimy. Médicaments de thérapie innovante et gestion des risques: quelle place pour le principe de précaution?. Journées Louis Dubouis organisées par N. de Grove-Valdeyron, Les nouveaux enjeux de la politique pharmaceutique européenne: pour des produits de santé sûrs, innovants et accessibles, May 2018, Toulouse, France. 〈halshs-01938434〉
  • Aurélie Mahalatchimy. The values of biomedical innovation: the legal view. EuroScience Open Forum, Jul 2018, Toulouse, France. 〈halshs-01938462〉

Poster1 document

  • Aurélie Mahalatchimy, John Gardner, Alex Faulkner, Andrew Webster, Claude Lemarié-Basset, et al.. The delivery of advanced therapies to patients: challenges and solutions. EuroScience Open Forum, Jul 2018, Toulouse, France. 〈halshs-01938479〉

Autre publication3 documents

  • Aurélie Mahalatchimy, Alex Faulkner. Conflicting values of biomedical innovation?. Available online at: https://www.euroscientist.com/conflicting-values-of-biomedical-innovation/ .. 2018. 〈halshs-01829660〉
  • Aurélie Mahalatchimy. Regulation of stem cell research in the United Kingdom. Lay overview of regulation of stem cell research in the UK for EuroStemCell Website. 2017. 〈halshs-01769219〉
  • Aurélie Mahalatchimy, Emmanuelle Rial-Sebbag. Regulation of stem cell research in France. Lay overview of regulation of stem cell research in France for EuroStemCell Website. 2017. 〈halshs-01769093〉